Kenta Yokote
YOU?
Author Swipe
View article: Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Purpose:Acquired or de novo resistance to immune checkpoint inhibitors occurs in the majority of advanced non–small cell lung cancers. There is an unmet need to improve outcomes for patients with this condition. Oncolytic viruses re…
View article: Supplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 4: Systemic therapy received by each patient prior to recruitment into the trial.
View article: Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 5. CAVATAK samples: time between biopsies and biopsy sites.
View article: Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
View article: Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 3: Antibodies used in the MIBI panel.
View article: Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 2. Representativeness of study participants
View article: New T Cell Subset Associated With Survival In Non-Small Cell Lung Cancer Identified with Hi-Plex Spatial Proteomics
New T Cell Subset Associated With Survival In Non-Small Cell Lung Cancer Identified with Hi-Plex Spatial Proteomics Open
View article: TNF⍰-mediated myeloid-instructed CD14<sup>+</sup>CD4<sup>+</sup>T cells within the tumor microenvironment are associated with poor survival in non-small cell lung cancer
TNF⍰-mediated myeloid-instructed CD14<sup>+</sup>CD4<sup>+</sup>T cells within the tumor microenvironment are associated with poor survival in non-small cell lung cancer Open
The tumor microenvironment (TME) harbors a diverse array of innate and adaptive immune cells that can either support anti-tumor immunity or facilitate tumor progression. Among these, myeloid cells are key drivers of immunosuppression, yet …
View article: Using random forests to uncover the predictive power of distance-varying cell interactions in tumor microenvironments
Using random forests to uncover the predictive power of distance-varying cell interactions in tumor microenvironments Open
Tumor microenvironments (TMEs) contain vast amounts of information on patient’s cancer through their cellular composition and the spatial distribution of tumor cells and immune cell populations. Exploring variations in TMEs between patient…
View article: Using random forests to uncover the predictive power of distance–varying cell interactions in tumor microenvironments
Using random forests to uncover the predictive power of distance–varying cell interactions in tumor microenvironments Open
Tumor microenvironments (TMEs) contain vast amounts of information on patient’s cancer through their cellular composition and the spatial distribution of tumor cells and immune cell populations. Exploring variations in TMEs among patients …
View article: Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer
Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer Open
View article: Early Immune Pressure Initiated by Tissue-Resident Memory T Cells Sculpts Tumour Evolution in Non-Small Cell Lung Cancer
Early Immune Pressure Initiated by Tissue-Resident Memory T Cells Sculpts Tumour Evolution in Non-Small Cell Lung Cancer Open